Similarly, DRD1 activation was suggested to be responsible for the enhanced antitumor activities in pancreatic cancer [12], although, in other tumor types, it behaves contradictorily (i.e., human hepatocellular carcinoma, breast cancer, etc.)[13,14]. This evidence concerns the gene DRD1 and pancreatic neoplasm.